- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Overview of Characteristics Unique to Ph+ ALL
A panel of medical experts break down the pathophysiology and current treatment landscape surrounding Ph+ ALL.
EP: 1.Overview of Characteristics Unique to Ph+ ALL
EP: 2.Timely Detection: Incidence and Prevalence of Ph+ ALL
EP: 3.Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life
EP: 4.Screening and Diagnosing of Ph+ ALL in Adults
EP: 5.Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management
EP: 6.Current Front-Line Targeted Treatments in Ph+ ALL
EP: 7.Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients
EP: 8.PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients
EP: 9.Value-Based Care Models Optimizing Ph+ ALL Patient Care
EP: 10.Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL
EP: 11.Disparities in Access to Care for Ph+ ALL patients
EP: 12.The Future of Ph+ ALL Treatments
EP: 13.Concluding Thoughts on Ph+ ALL Treatment
The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Jonathon Abbas, MD; Vivian Tambe Tar, PharmD, MBA; Elias Jabbour, MD; and James McCloskey, MD.
This Peer Exchange brings together experts in the field to discuss the clinical intricacies of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The discussion centers on the disease's rarity, affecting only a fraction of acute leukemia cases, with an emphasis on the need for personalized treatment approaches due to the diverse age range of patients.
Dr. Abbas delves into the clinical characteristics that define Ph+ ALL, highlighting its scarcity and the challenges it poses to healthcare providers. Dr. Jabbour expands on the age-related incidence of the disease, discussing peaks in pediatric and older populations. The conversation underscores the evolving landscape, with improved therapies, such as tyrosine kinase inhibitors, offering hope for better outcomes. The panel concludes by addressing gender and race neutrality while emphasizing the significance of considering comorbidities in older patients. The program anticipates a shift in treatment paradigms with targeted therapies, marking a positive trajectory in managing Ph+ ALL and enhancing patient outcomes.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More
